Drugs / ABBV-295
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07514260 | Mar 2026 → Jan 2027 expected | — | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT07414784 | Feb → Jul 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07291232 | Nov 2025 → Oct 2026 expected | obesity disorder | AbbVie | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-09 | AbbVie | AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults abbvie.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-295 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07291232 ↗ |
| Route | Subcutaneous | “subcutaneous doses of ABBV-295” NCT07291232 ↗ |